您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > GSK2636771
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
GSK2636771
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1372540-25-4
包装与价格:
包装价格(元)
1 mg电议
5 mg电议
10 mg电议
50 mg电议
100 mg电议
1 mL*10 mM(in DMSO)电议

产品名称
GSK 2636771
GSK-2636771
产品介绍
GSK2636771 是选择性的、口服有效的PI3Kβ抑制剂,Ki=0.89 nM,IC50=5.2 nM,比p110α和p110γ的选择性高900倍,比p110δ同种型的选择性高10倍。

产品描述

GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neoplasm.

体外活性

在小鼠中,GSK-2636771 (100 mg/kg)不增加葡萄糖/胰岛素水平.在移植瘤模型中,GSK-2636771降低磷酸化的蛋白激酶Akt(Ser473)水平.

体内活性

在PTEN缺失细胞系中,GSK-2636771具有特异的抑制活性,在人前列腺癌PC-3(EC50=36 nM)和乳腺癌HCC70(EC50=72 nM)。

细胞实验

Cells are plated in 96-well microtiter plates at densities ranging from 1,500 to 15,000 cells/well, optimized for untreated control cells to be 80-90% confluent at the endpoint of the experiment. After 24 h, cells are treated with serial dilutions (100pM to 10μM) of GSK2636771. Cell viability is assessed after 72 h of treatment by incubation with CellTiter Blue for 1.5 h. The drug concentration requires for survival of 50% of cells relative to untreated cells (surviving fraction 50, SF50) is determined using GraphPad Prism version 5.0d. Cell lines that fails to achieve the SF50 to a given drug are nominally assigned as the highest concentration screened (i.e. 10μM). At least three independent experiments in triplicate per cell line targeted drug are performed. Association between a mutation and response to a targeted agent is determined using a Fisher’s exact test (GraphPad Prism), and a two-tailed P value <0.05 is considered statistically significant. (Only for Reference)

Cas No.

1372540-25-4

分子式

C22H22F3N3O3

分子量

433.42

别名

GSK 2636771;GSK-2636771;GSK2636771

储存和溶解度

H2O:<1 mgml
DMSO:27 mg/mL (62.3 mM)
Ethanol:<1 mgml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years